Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

192
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
192
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

378
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
378
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

369
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
369
Pneumonia IV: Management01:28

Pneumonia IV: Management

655
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
655
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

811
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
811
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

333
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
333

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Small airway dysfunction: a key predictor of exacerbation risk in adolescents with mild, well-controlled asthma.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Delayed Diagnosis of Cystic Fibrosis and Nontuberculous Mycobacterial Infection in Refractory CRSwNP.

Respirology case reports·2026
Same author

Interpreting Win Ratios in COPD From BOREAS and NOTUS.

Chest·2026
Same author

Combined large and small airway obstruction is associated with increased exacerbation frequency and poorer symptom control in persistent asthma.

The journal of allergy and clinical immunology. In practice·2026
Same author

Relationships Between Bronchodilator Reversibility and Mannitol Airway Hyperresponsiveness in Severe Asthma.

Clinical and translational allergy·2026
Same author

Real-world effectiveness of tezepelumab on clinical remission and small airway dysfunction in severe asthma: a 52-week prospective study.

Expert opinion on biological therapy·2026

Related Experiment Video

Updated: Dec 17, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.2K

Emerging pharmacotherapy for COVID-19.

Brian Lipworth1, Chris RuiWen Kuo2, Rory Chan2

  • 1Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK,

The Journal of the Royal College of Physicians of Edinburgh
|June 23, 2020
PubMed
Summary

Pharmacological treatments for COVID-19 target viral replication or immune response. Combination therapies addressing both may be crucial for preventing severe disease in at-risk patients.

Keywords:
ACE2ARDSCOVID-19SARS-CoV-2TMPRSS2antiviralscomorbiditycorticosteroidcytokinehyperinflammationpneumonia

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.7K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K

Related Experiment Videos

Last Updated: Dec 17, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.2K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.7K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Immunology

Background:

  • COVID-19 treatments target viral replication (upstream) or immune response (downstream).
  • Existing treatments like remdesivir and interferon beta-1b show variable efficacy.
  • Hydroxychloroquine has yielded disappointing results.

Purpose of the Study:

  • To review current pharmacological approaches for COVID-19.
  • To evaluate the potential of combination therapies for severe COVID-19.
  • To identify the need for targeted studies in high-risk populations.

Main Methods:

  • Review of existing clinical trial data and pharmacological mechanisms.
  • Analysis of upstream (antiviral) and downstream (anti-inflammatory) treatment strategies.
  • Consideration of patient subgroups, including older individuals with comorbidities.

Main Results:

  • Antiviral drugs like remdesivir can shorten disease duration.
  • Interferon beta-1b may accelerate viral clearance.
  • Selective cytokine blockers (anti-IL-1, anti-IL-6) show promise in severe cases, requiring further validation.

Conclusions:

  • Combination therapy targeting both viral replication and immune response is likely necessary for severe COVID-19.
  • Further research is warranted to optimize treatment strategies for high-risk patients.
  • Targeted interventions are crucial for improving outcomes in susceptible populations.